Previous Close | 21.37 |
1-Year Change | 16.39% |
6-Months Change | -7.17% |
3-Months Change | -11.62% |
Moving Avg (50d) | 22.091 |
Moving Avg (200d) | 23.59 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.95B |
Beta (3-Years) | 1.68 |
Revenue Growth (ttm) | 207.89% |
Net Profit Margin (ttm) | -36.51% |
Return On Assets (ttm) | -10.06% |
EPS (ttm) | -0.97 |
PE Ratio (ttm) | -22.03 |
Dividend Yield | % |
Asset Description: | Denali Therapeutics Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-02-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
21.797 | 22.439 | 22.866 | 23.507 | 24.576 | 25.644 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |